Iradimed Corp (IRMD) Given Average Rating of “Buy” by Brokerages

Shares of Iradimed Corp (NASDAQ:IRMD) have been assigned an average rating of “Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $24.67.

A number of equities analysts recently commented on IRMD shares. TheStreet raised Iradimed from a “c+” rating to a “b-” rating in a research note on Monday, August 27th. BidaskClub lowered Iradimed from a “buy” rating to a “hold” rating in a research note on Friday, October 12th. ValuEngine raised Iradimed from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 22nd. Finally, Roth Capital lifted their price objective on Iradimed from $21.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, August 1st.

In other Iradimed news, VP Francis X. Casey sold 55,000 shares of the business’s stock in a transaction that occurred on Friday, September 14th. The stock was sold at an average price of $29.30, for a total value of $1,611,500.00. Following the transaction, the vice president now directly owns 98,779 shares of the company’s stock, valued at $2,894,224.70. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Steven M. Nardi sold 7,662 shares of the business’s stock in a transaction that occurred on Thursday, August 2nd. The shares were sold at an average price of $23.80, for a total value of $182,355.60. Following the completion of the transaction, the vice president now directly owns 5,162 shares in the company, valued at $122,855.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 231,556 shares of company stock worth $6,209,841. 61.20% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Northern Trust Corp lifted its stake in Iradimed by 27.9% in the first quarter. Northern Trust Corp now owns 26,791 shares of the medical equipment provider’s stock valued at $386,000 after buying an additional 5,850 shares during the period. Bank of New York Mellon Corp lifted its stake in Iradimed by 46.4% in the second quarter. Bank of New York Mellon Corp now owns 22,588 shares of the medical equipment provider’s stock valued at $469,000 after buying an additional 7,156 shares during the period. EAM Investors LLC lifted its stake in Iradimed by 25.0% in the second quarter. EAM Investors LLC now owns 36,774 shares of the medical equipment provider’s stock valued at $763,000 after buying an additional 7,348 shares during the period. Bank of America Corp DE lifted its stake in Iradimed by 3,722.5% in the second quarter. Bank of America Corp DE now owns 14,793 shares of the medical equipment provider’s stock valued at $307,000 after buying an additional 14,406 shares during the period. Finally, Russell Investments Group Ltd. lifted its stake in Iradimed by 68.8% in the first quarter. Russell Investments Group Ltd. now owns 59,118 shares of the medical equipment provider’s stock valued at $834,000 after buying an additional 24,097 shares during the period. 19.86% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:IRMD opened at $27.32 on Thursday. The stock has a market cap of $396.77 million, a PE ratio of 341.50 and a beta of 1.44. Iradimed has a 1-year low of $9.75 and a 1-year high of $38.78.

Iradimed (NASDAQ:IRMD) last posted its quarterly earnings data on Tuesday, July 31st. The medical equipment provider reported $0.14 EPS for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.04. The company had revenue of $7.38 million for the quarter, compared to analyst estimates of $7.26 million. Iradimed had a return on equity of 8.99% and a net margin of 9.57%. On average, research analysts anticipate that Iradimed will post 0.37 EPS for the current year.

Iradimed Company Profile

IRadimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name.

Read More: What is a conference call?

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply